obotic prostate cancer surgery has transformed how prostate cancer is treated, offering men less invasive procedures, faster recovery, and precise cancer control. In 2026, these surgeries are more advanced than ever, thanks to improvements in robotic technology, imaging, and surgical techniques.
Professor Prokar Dasgupta OBE remains at the forefront of these innovations. As one of the world’s leading robotic urological surgeons, he has pioneered techniques that improve outcomes for patients undergoing radical robotic prostatectomy. His work focuses on refining nerve-sparing procedures, reducing complications, and utilising state-of-the-art robotic platforms to enhance surgical accuracy.
Recent advances in robotic prostate surgery include:
- Enhanced 3D imaging and navigation: Surgeons can now visualise the prostate and surrounding tissues in exceptional detail, allowing precise removal of cancer while sparing nerves critical for continence and sexual function.
- Smaller, more precise incisions: Modern robotic arms enable minimal tissue trauma, reducing post-operative pain and shortening hospital stays.
- Integration of AI and real-time analytics: AI-supported systems help surgeons plan the surgery and make data-driven decisions during the operation.
- Personalised surgical planning: MRI and 3D modelling allow a patient-specific approach, tailoring the procedure to each individual’s anatomy and cancer characteristics.
These improvements not only enhance cancer control but also help patients recover faster and maintain a better quality of life after surgery. Patients under Professor Dasgupta’s care benefit from these innovations alongside his decades of experience, ensuring expert surgical care with a patient-centred approach.
As robotic prostate surgery continues to evolve, choosing an experienced surgeon like Prokar Dasgupta ensures access to the latest techniques and the highest standards of care. Understanding the technology and its benefits empowers patients to make informed decisions about their prostate cancer treatment in 2026 and beyond.